ABCL — AbCellera Biologics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1703057 ·
Last close
$12.70
Market Cap
$4.12B
52W High
$13.18
52W Low
$2.74
ADV30
5,401,040
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 4,050,000 — -58,923,000 -55,427,000 1,307,575,000 120,065,000 411,555,000
Mar 2026 8,315,000 — -53,180,000 -43,165,000 1,307,112,000 77,063,000 369,029,000
Dec 2025 44,853,000 — -25,266,000 -8,945,000 1,356,950,000 128,513,000 390,046,000
Sep 2025 8,955,000 — -73,549,000 -57,119,000 1,355,992,000 83,159,000 391,954,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-94,937,000
Investing CF
$97,886,000
Financing CF
$25,072,000
CapEx
$-24,734,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.63
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-128,074,000
Inventory
$7,578,000
Receivables
$95,425,000
ST Investments
$420,039,000
EBIT TTM
$-210,918,000
Pretax Income TTM
$-196,769,000
Interest Exp TTM
$42,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$66,170,000
EBITDA
$-199,960,000
Free Cash Flow
$-46,431,124
Enterprise Value
$2,934,511,872
Total Cash
$540,104,000
Total Debt
$135,616,992
Shares Out
324,047,363
Trailing EPS
$-0.54
Book Value
$2.92
ROE
-17.3%
ROA
-10.4%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 75,128,000 -203,213,000 -146,412,000 1,356,950,000 390,046,000 966,904,000 -131,295,000
Dec 2024 28,833,000 -301,146,000 -162,857,000 1,360,553,000 304,469,000 1,056,084,000 -108,556,000
Dec 2023 38,025,000 -223,052,000 -146,398,000 1,488,094,000 335,776,000 1,152,318,000 -43,877,000
Dec 2022 485,424,000 227,065,000 158,519,000 1,540,907,000 307,630,000 1,233,277,000 277,360,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$112,125,000
NetIncome TTM
$-70,104,000
OpCashFlow TTM
$0
Assets (Latest)
$1,356,950,000
Forward EPS
$-0.71

Max Pain — expiry 2026-10-16

max pain strike: $11.00 · spot: $13.15 · call oi: 18,393 · put oi: 8,897
Expected Move to 2026-10-16: ±$1.95 (14.83%) — implied range $11.20 – $15.10 · ATM straddle on $13.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VKTX Viking Therapeutics, Inc. $4.15B $35.56 —
TNGX Tango Therapeutics, Inc. $4.20B $24.92 —
INDV Indivior Pharmaceuticals, Inc. $4.23B $35.82 —
EWTX Edgewise Therapeutics, Inc. $4.27B $39.34 —
TLX Telix Pharmaceuticals Ltd $3.89B $11.45 —

News headlines (Yahoo Finance, 1h cache)

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
2026-09-16 20:05 · Yahoo
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
2026-08-14 22:53 · Yahoo
AbCellera (ABCL) Q2 2026 Earnings Call Transcript
2026-08-13 00:31 · Yahoo
AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?
2026-08-12 07:10 · Yahoo
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal
2026-08-12 06:14 · Yahoo
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results
2026-08-11 21:11 · Yahoo
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
2026-08-11 02:31 · Yahoo
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook
2026-08-10 21:40 · Yahoo
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
2026-08-13 04:05 · Yahoo
AbCellera Stock Jumps 33% on a Positive Menopause Trial
2026-08-10 16:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.